Mode
Text Size
Log in / Sign up
N/A N=119 Treatment

Navi-Star Thermo-Cool Catheter For Ablation of Atrial Fibrillation

Paroxysmal Atrial Fibrillation

Enrolled (actual)
119
Serious AEs
8.4%
Results posted
Jul 2014
Primary outcome: Primary: Atrial Tachyarrhythmia Recurrence in Participants — 37 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
GP ablation + PV isolation (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Oklahoma
Primary completion
Feb 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Atrial Tachyarrhythmia Recurrence in Participants
37
SECONDARY
Total Number of Significant Ablation Procedure Related Complications
10

Summary

The objective of this study is to demonstrate that the NAVI-STAR THERMO-COOL catheter can be used to safely and effectively reduce symptomatic episodes of paroxysmal atrial fibrillation in patients with frequent (>3 episodes/month) or infrequent <3 episodes/month)atrial fibrillation resistant to at least one Class I or Class III antiarrhythmic drug.

Eligibility Criteria

Inclusion Criteria

  • Age greater or equal to 18 years
  • At least one documented episode of atrial fibrillation (AF) within the previous 6 months.
  • Failure of at least one antiarrhythmic drug (Class I or III) defined as recurrence of AF or adverse effect.
  • Informed consent obtained.

Exclusion Criteria

  • Left atrial thrombus
  • Acute myocardial infarction within eight (8) weeks
  • Atriotomy within eight (8) weeks
  • Decompensated heart failure (unless the AF is thought to be a significant etiologic factor and AF ablation is clinically indicated)
  • Pregnancy
  • Ablation in a pulmonary vein within 4 months.
  • Occurrence of perforation during an ablation procedure performed less than two months prior to the planned ablation date.
  • Significant congenital anomaly or medical problem that, in the opinion of the investigator, would preclude enrollment in the study.
  • Enrolled in an investigational study evaluating another device or drug
  • Unwilling to participate in the study or unavailable for follow-up visits.
  • Incarcerated
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00584415). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search